For HCPs - Clear Study

Caring for patients with early-stage CSCC?

Talk to your patients about CLEAR

With limited treatment options and the growing need for non-surgical management of early-stage cutaneous squamous cell cancer (CSCC), the CLEAR clinical research study is currently underway to investigate potential non-surgical treatments. Consider the CLEAR study as an opportunity for your patients with early-stage CSCC to access experimental treatments.

CLEAR is a phase 3 clinical study for adults with Stage 1 CSCC (Head & Neck, Hand, and Pre-tibial Areas). This study is evaluating the efficacy and safety of a PD1 inhibitor administered intralesionally compared to a standard of care treatment (primary surgery) in patients with early-stage CSCC.

How can you help?

CLEAR is enrolling approximately 369 people with early-stage CSCC worldwide. The success of CLEAR depends on physicians to refer potential study participants. Your patients may be eligible if they:

Are 18 years old or older

Were diagnosed with early-stage CSCC

Are appropriate candidates for surgery

Have ECOG performance status ≤ 1

Have not received prior systemic therapy for CSCC

Please note: Other protocol-defined inclusion/exclusion criteria apply.

The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.

If you have potentially eligible and interested patients, empower them with options and discuss the CLEAR study. You may also contact the nearest study site to refer them.

Caring for patients with early-stage CSCC?

Talk to your patients about CLEAR

How can you help?

Find a study site near you!